Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, announced terms for its IPO on Thursday.The New Haven, CT-based company plans to raise $81 million by offering 5.8 million shares at a price range of $13 to $15. At the midpoint of the proposed range,IPOs Feed

By

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.